Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.

Stephen A SpectorSean S BrummelAudrey ChangAndrew WizniaTheodore D RuelEdward P Acostanull null

Published in: Journal of acquired immune deficiency syndromes (1999) (2024)

Dolutegravir AUC 24 for genetic variants in ABCG2 , NR1l2 , and UGT1A1 varied from -25% to +33%. These findings help to explain some of the variable pharmacokinetics identified with dolutegravir in children.

Keyphrases

hiv infected patients
antiretroviral therapy
young adults